It is very uncertain whether summary of findings table ‐ Gabapentin changes risk for at least one adverse event per patient compared with pregabalin (very low certainty).
It is very uncertain whether summary of findings table ‐ Ondansetron changes risk for at least one adverse event per patient compared with placebo (very low certainty).
It is very uncertain whether summary of findings table ‐ Cromolyn sodium changes risk for at least one adverse event per patient compared with placebo (very low certainty).
Summary of findings table ‐ Topical capsaicin may leads to higher risk for at least one adverse event per patient compared with placebo (low certainty).
Summary of findings table ‐ GABA‐analogues showed no clear difference in risk for at least one adverse event per patient compared with placebo (low certainty).
Summary of findings table ‐ Naltrexone may leads to higher risk for at least one adverse event per patient compared with placebo (low certainty).
It is very uncertain whether summary of findings table ‐ Rifampin/rifampicin changes risk for at least one adverse event per patient compared with placebo (very low certainty).
The review found no eligible studies for this question.